Back to results
US 11,433,106 B2Granted
Compositions comprising bacterial strains
Assignee4D Pharma Research Limited
InventorsGeorge Grant, Angela Margaret Patterson, Imke Mulder, Seanin McCluskey, Emma Raftis
Life of this patent
Estimating the term…
Abstract
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
Claims18
A method of treating inflammation characterized by an elevated level of interferon-γ (IFN-γ) and interleukin-10 (IL-10) in a subject in need thereof, comprising:
- administering to said subject a therapeutically effective amount of a pharmaceutical composition that comprises at least 1×103 colony forming units (CFU)/g of a bacteria strain of the species Parabacteroides distasonis with respect to a total weight of said pharmaceutical composition;
- wherein said bacteria strain comprises a 16s rRNA gene sequence with at least 99.5% sequence identity to the sequence of SEQ ID NO:1 or at least 99% sequence identity to the sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:9, as determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2;
- and
- wherein said therapeutically effective amount is effective to reduce said level of IFN-γ and IL-10, as compared to prior to said administering, thereby treating said inflammation in said subject.
1 more element
A method of treating inflammation characterized by an elevated level of interleukin-10 (IL-10) in a subject in need thereof, comprising:
- administering to said subject a therapeutically effective amount of a pharmaceutical composition that comprises at least 1×103 colony forming units (CFU)/g of a bacteria strain of the species Parabacteroides distasonis with respect to a total weight of said pharmaceutical composition;
- wherein said bacteria strain totally or partially colonizes the intestine when administered to said subject;
- wherein said bacteria strain comprises a 16s rRNA gene sequence with at least 99.5% sequence identity to the sequence of SEQ ID NO:1 or at least 99% sequence identity to the sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:9, as determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2;
- and
- wherein said therapeutically effective amount is effective to reduce said level of IL-10, as compared to prior to said administering, thereby treating said inflammation in said subject.
2 more elements
Dependencies are inferred from the claim text.